Shares of Ambrx Biopharma Inc. (AMAM) are surging more than 50% after the company announced encouraging initial data from the ongoing Phase 1 study of ARX517 in patients with advanced prostate cancer.
In the Phase 1 study dubbed APEX-01, Prostate-specific antigen (PSA) reductions ranging from more than 30% to 90% was observed in prostate cancer patients who were treated with ARX517, the company said.
AMAM is at $2.88 currently. It has traded in the range of $0.3800-$5.1200 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.